Stromal haze after combined riboflavin‐UVA corneal collagen cross‐linking in keratoconus: <i>in vivo</i> confocal microscopic evaluation

Mazzotta, Cosimo; Balestrazzi, Angelo; Baiocchi, Stefano; Traversi, Claudio; Caporossi, Aldo

doi:10.1111/j.1442-9071.2007.01536.x

Cited by 217 publications

(157 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Despite the overall enthusiasm for offering CXL to KC patients, adverse events have been incompletely assessed in the literature. 13,14 Koller et al 9 reported an overall adverse event rate of 2.9% in 105 eyes, and identified age Z35 years as the most important independent risk factor for adverse events after CXL. However, this findings needs to be interpreted cautiously, because, given the figures provided in the paper, the estimated number of eyes in patients aged 435 years enrolled in the Koller study was only 15 with 2 failures, corresponding to a mean probability of 0.13 and a binomial exact 95% CI of 0.02-0.40.…”

Section: Resultsmentioning

confidence: 99%

Effects and adverse events after CXL for keratoconus are independent of age: a 1-year follow-up study

Baenninger

Bachmann

Wienecke

et al. 2014

Eye

View full text Add to dashboard Cite

Purpose To compare the effect, failure rate and the risks of corneal cross-linking (CXL) in keratoconus patients aged Z35 years to patients o35 years. Methods In 141 eyes of 116 keratoconus patients we compared the changes in best phoropter-corrected visual acuity (BCVA) and maximum keratometry values (K max ) before and 12 months after CLX in patients aged Z35 years (n ¼ 34, 38 eyes) to the cohort of patients below 35 years of age. Results Overall, CXL significantly improved BCVA from 0.487 logMAR (95% confidence interval (CI) 0.426-0.548) by À 0.197 logMAR (95% CI À 0.243 to À 0.150; Po0.001) and reduced K max from 48.96 diopter (Dpt) by À 1.33 Dpt (95% CI À 1.85 to À 0.81: Po0.001). Age Z35 years had no effect on the changes of BCVA ( À 0.02 (95% CI À 0.13 to 0.09); P ¼ 0.757) or K max (0.58 (95%CI À 0.51 to 1.68); P ¼ 0.294) as compared with younger patients. In 54 patients (55 eyes, 38.5%) aged o35 years and in 18 patients (18 eyes, 47.4%) aged Z35 years, BCVA increased by Z2 Snellen lines. Failure (increase in K max Z1 Dpt) was observed in 17 eyes (16.5%) of patients aged o35 years and in 3 eyes (7.9%) of patients aged Z35 years during the 12-month follow-up period. Adverse outcomes (loss of Z2 Snellen lines) occurred in 4 (3.9%) eyes of patients aged o35 years and 1 (2.6%) eye of a patient aged Z35 years. Conclusion Effects and adverse events of CXL treatment do not seem to differ between subjects younger or older than 35 years.

show abstract

Section: Resultsmentioning

confidence: 99%

Effects and adverse events after CXL for keratoconus are independent of age: a 1-year follow-up study

Baenninger

Bachmann

Wienecke

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

“…All trials have indicated a time-dependence of the effects of CXL, both in terms of transient haze 54 and edema in the early stages, as well as in refractive outcome, which seems to improve over the first year or more following treatment 26,30,31,[51][52] .…”

Section: Effect Of the Treatment On Cornea Claritymentioning

confidence: 99%

Corneal Collagen Crosslinking with Riboflavin and Ultraviolet - A Irradiation in the Management of Progressive Ectatic Corneal Disorders. Review Article

Eldine

2017

Journal of Ophthalmology and Related Sciences

View full text Add to dashboard Cite

Corneal crosslinking (CXL) has been proposed as a new modality to stop progression of keratoconus or secondary corneal ectasia, aiming to prevent progressive visual loss and to delay or avoid corneal transplantation. The possibility of strengthening corneal tissue by means of a photochemical reaction of corneal collagen by the combined action of riboflavin and ultraviolet-A irradiation (UVA), radically modified the conservative management of progressive corneal ectasia. This is a review of the state of the art of CXL. The paper describes basic principles, advantages and limitations of different CXL techniques and possible future evolution of the procedure.

show abstract

“…Despite the fact that no sight-threatening complications were recorded in the large prospective studies, there are some sporadic reports of stromal haze resistant to topical steroid treatment (Mazzota et al, 2007), diffuse lamellar keratitis in post-LASIK ectasia, herpetic keratitis and iritis , Acanthamoeba keratitis with corneal perforation (Rama et al, 2009), and microbial keratitis (Pollhammer & Cursiefen, 2009;Zamora & Males, 2009). Other potential complications include delay in reepithelization, sterile infiltrates, potential for induction of herpes simples virus and dendritic ulcer, and ocular surface disorders and tear dysfunction (Corkin, 2009).…”

Section: Treatmentmentioning

confidence: 99%

Etiology and Clinical Presentation of Astigmatism

Olujić¹

2012

Advances in Ophthalmology

View full text Add to dashboard Cite

Stromal haze after combined riboflavin‐UVA corneal collagen cross‐linking in keratoconus: in vivo confocal microscopic evaluation

Cited by 217 publications

References 5 publications

Effects and adverse events after CXL for keratoconus are independent of age: a 1-year follow-up study

Effects and adverse events after CXL for keratoconus are independent of age: a 1-year follow-up study

Corneal Collagen Crosslinking with Riboflavin and Ultraviolet - A Irradiation in the Management of Progressive Ectatic Corneal Disorders. Review Article

Etiology and Clinical Presentation of Astigmatism

Contact Info

Product

Resources

About